Raia Drogasil (OTCMKTS:RADLY) Shares Gap Down – What’s Next?

Raia Drogasil S.A. (OTCMKTS:RADLYGet Free Report)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $3.96, but opened at $3.82. Raia Drogasil shares last traded at $3.82, with a volume of 5,724 shares trading hands.

Raia Drogasil Trading Down 2.3%

The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.58 and a current ratio of 1.41. The stock has a fifty day moving average price of $3.70 and a 200 day moving average price of $3.95. The stock has a market cap of $5.09 billion and a PE ratio of 77.40.

Raia Drogasil (OTCMKTS:RADLYGet Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. Raia Drogasil had a net margin of 2.97% and a return on equity of 18.20%. The company had revenue of $2.17 billion for the quarter, compared to analyst estimates of $2.32 billion. Equities analysts expect that Raia Drogasil S.A. will post 0.17 EPS for the current year.

Raia Drogasil Company Profile

(Get Free Report)

Raia Drogasil, now operating under the brand name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a nationwide network of pharmacies that sells prescription and over-the-counter medicines, personal-care products, cosmetics, health and wellness items, and convenience products.

The company also provides digital shopping and delivery services through its online channels, supporting customers with medication and health-related purchases. Its operations combine physical stores with e-commerce and other healthcare-related services, serving consumers throughout Brazil.

RD Saúde was formed in 2011 through the merger of Drogasil and Droga Raia, two pharmacy chains with roots dating back to the early twentieth century.

Featured Stories

Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.